1-Marotta V, Ramundo V, Camera L et al. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin Endocrinol (Oxf) 2013 May;78(5):760-767.
2-Cabanillas ME1 , Waguespack SG, Bronstein Y, et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. J Clin Endocrinol Metab 2010 Jun;95(6):2588-2595.
3-Chrisoulidou A, Mandanas S, Margaritidou E,et al. Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer. Onco Targets Ther 2015;8:2435-2442.
4- Hamson EJ, Keane FM, Tholen S, Schilling O, Gorrell MD. Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. Proteomics Clin Appl. 2014 Jun;8(5-6):454-63.
5- Gorrell, M. D., Park, J. E., in: Rawlings, N. L., Salvesen, G. (Eds.), Handbook of Proteolytic Enzymes, 3rd edition, Else- vier, San Diego 2013, pp. 3395–3401.
6- Aertgeerts, K., Levin, I., Shi, L., Snell, G. P. et al., Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein Alpha. J. Biol. Chem. 2005, 280, 19441–19444.
7- Bauer, S., Jendro, M. C., Wadle, A., Kleber, S. et al., Fi- broblast activation protein is expressed by rheumatoid myofibroblast-like synoviocytes. Arthritis Res. Ther. 2006, 8, R171.
8- Wang, X. M., Yu, D. M. T., McCaughan, G. W., Gorrell, M. D., Fibroblast activation protein increases apoptosis, cell ad- hesion and migration by the LX-2 human stellate cell line. Hepatology 2005, 42, 935–945.
9- Brokopp, C. E., Schoenauer, R., Richards, P., Bauer, S. et al., Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur. Heart J. 2011, 32, 2713–2722.
10- Siveke JT. Fibroblast-activating protein: targeting the roots of the tumor microenvironment. J NuclMed. 2018;59:1412–1414.
11- Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, Adeberg S, Rathke H, Röhrich M, Winter H, Plinkert PK, Marme F, Lang M, Kauczor HU, Jäger D, Debus J, Haberkorn U, Giesel FL. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med. 2019 Jun;60(6):801-805.
12- Davies L, Welch HG. Current thyroid cancer trends in the United States. JAMA Otolaryngol Head Neck Surg. 2014 Apr;140(4):317-22.
13- Brito JP, Morris JC, Montori VM. Thyroid cancer: zealous imaging has increased detection and treatment of low risk tumours. BMJ. 2013 Aug 27;347:f4706.
14- Piccardo A, Puntoni M, Bertagna F, et al. (1)(8)F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. Eur J Nucl Med Mol Imaging. 2014;41:1482-1491.
15- Kim SK, So Y, Chung HW, et al. Analysis of predictability of F-18 fluorodeoxyglucose-PET/CT in the recurrence of papillary thyroid carcinoma. Cancer Med. 2016;5:2756-2762.
16- Thompson LD. Ninety-four cases of encapsulated follicular variant of papillary thyroid carcinoma: A name change to Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features would help prevent overtreatment. Mod Pathol. 2016 Jul;29(7):698-707.
17- Antonelli A., Fallahi P., Ferrari S.M., Carpi A., Berti P., Materazzi G., Minuto M., Guastalli M., Miccoli P. Dedifferentiated thyroid cancer: A therapeutic challenge. Biomed. Pharmacother. 2008;62:559–563.
18- Hanna G.J., Busaidy N.L., Chau N.G., Wirth L.J., Barletta J.A., Calles A. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin. Canc. Res. 2018;24:1546–1553.
19- Lin JD. Thyroglobulin and human thyroid cancer. Clin Chim Acta. 2008 Feb;388(1-2):15-21.
20- Taveira M. Comparison of 68Ga-FAPI versus 18F-FDG PET/CT for Initial Cancer Staging. Radiol Imaging Cancer. 2021 Mar 26;3(2):e219007.
21- Chen H, Pang Y, Wu J, et al. Comparison of [68Ga]Ga-DOTA-FAPI-04 and [18F] FDG PET/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging 2020;47;1820–1832.
22- Ou L, Wu J, Yang F, Zhang C. Comparison of 68 Ga-FAPI and 18 F-FDG PET/CT inmetastasis of thyroid papillary carcinoma. Hell J Nucl Med. 2021 Jan-Apr;24(1):100-101.